Kenpack Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 0.50 M
as on 26-07-2024
- Company Age 27 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 13.87%
(FY 2023)
- Profit -3.29%
(FY 2023)
- Ebitda -55.66%
(FY 2023)
- Net Worth 44.18%
(FY 2023)
- Total Assets 4462.45%
(FY 2023)
About Kenpack Pharma
The Corporate was formerly known as Kenpack Pharma Limited. The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Mahesh Ladha, Sunil Kedia, and Jyotiprasad Taparia serve as directors at the Company.
- CIN/LLPIN
U24232MH1997PTC252707
- Company No.
252707
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 1997
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kenpack Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Ladha  | Director | 10-Aug-2023 | Current |
| Sunil Kedia | Director | 30-Sep-2019 | Current |
| Jyotiprasad Taparia | Director | 04-Jul-1997 | Current |
Financial Performance and Corporate Structure Insights of Kenpack Pharma.
Kenpack Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.87% increase. The company also saw a slight decrease in profitability, with a 3.29% decrease in profit. The company's net worth Soared by an impressive increase of 44.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kenpack Pharma?
In 2022, Kenpack Pharma had a promoter holding of 99.92% and a public holding of 0.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elegare Beauty Private LimitedActive 8 years 6 monthsMahesh Ladha and Jyotiprasad Taparia are mutual person
Famy Care Private LimitedActive 37 years 2 monthsMahesh Ladha, Sunil Kedia and 1 more are mutual person
Guardian Nutrition And Healthcare Private LimitedActive 8 years 6 monthsMahesh Ladha is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kenpack Pharma?
Kenpack Pharma has a workforce of 22 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kenpack Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kenpack Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
